SAN

80.93

-3.14%↓

UCB

240.7

-2.31%↓

SHL.DE

35.52

-2.55%↓

ARGX

669

-0.59%↓

VIE

35.38

+0.23%↑

SAN

80.93

-3.14%↓

UCB

240.7

-2.31%↓

SHL.DE

35.52

-2.55%↓

ARGX

669

-0.59%↓

VIE

35.38

+0.23%↑

SAN

80.93

-3.14%↓

UCB

240.7

-2.31%↓

SHL.DE

35.52

-2.55%↓

ARGX

669

-0.59%↓

VIE

35.38

+0.23%↑

SAN

80.93

-3.14%↓

UCB

240.7

-2.31%↓

SHL.DE

35.52

-2.55%↓

ARGX

669

-0.59%↓

VIE

35.38

+0.23%↑

SAN

80.93

-3.14%↓

UCB

240.7

-2.31%↓

SHL.DE

35.52

-2.55%↓

ARGX

669

-0.59%↓

VIE

35.38

+0.23%↑

Search

Fagron

Atidarymo kaina

SektoriusSveikatos priežiūra

23.5 -1.05

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

23.45

Max

23.8

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-99K

45M

Pardavimai

-98K

476M

P/E

Sektoriaus vid.

19.557

60.328

Dividendų pajamingumas

1.64

Pelno marža

9.55

Darbuotojai

4,193

EBITDA

11M

98M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.64%

2.24%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

149M

1.8B

Ankstesnė atidarymo kaina

24.55

Ankstesnė uždarymo kaina

23.5

Naujienos nuotaikos

By Acuity

50%

50%

178 / 348 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-24 00:00; UTC

Uždarbis

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026-04-24 00:00; UTC

Uždarbis

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026-04-23 23:47; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

2026-04-23 23:13; UTC

Įsigijimai, susijungimai, perėmimai

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

2026-04-23 22:33; UTC

Uždarbis

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

2026-04-23 22:17; UTC

Uždarbis

PLS Executed Offtake Agreement With Ronbay

2026-04-23 22:17; UTC

Uždarbis

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

2026-04-23 22:16; UTC

Uždarbis

PLS Commences Commissioning of Midstream Demonstration Plant

2026-04-23 22:15; UTC

Uždarbis

PLS Group Reaffirms FY26 Guidance for All Metrics

2026-04-23 22:14; UTC

Uždarbis

PLS Group 3Q Cash Margin From Operations A$461M at March 31

2026-04-23 22:14; UTC

Uždarbis

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

2026-04-23 22:13; UTC

Uždarbis

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

2026-04-23 22:12; UTC

Uždarbis

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

2026-04-23 22:12; UTC

Uždarbis

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

2026-04-23 22:11; UTC

Uždarbis

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

2026-04-23 22:10; UTC

Uždarbis

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

2026-04-23 22:09; UTC

Uždarbis

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

2026-04-23 22:08; UTC

Uždarbis

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

2026-04-23 22:04; UTC

Uždarbis

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

2026-04-23 21:56; UTC

Rinkos pokalbiai
Uždarbis

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

2026-04-23 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026-04-23 21:27; UTC

Uždarbis

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

2026-04-23 21:25; UTC

Uždarbis

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

2026-04-23 21:24; UTC

Uždarbis

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

2026-04-23 21:24; UTC

Uždarbis

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

2026-04-23 21:21; UTC

Uždarbis

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

2026-04-23 21:21; UTC

Uždarbis

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

178 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat